Comparative Pharmacology
Head-to-head clinical analysis: AMMONIA N 13 versus PYLARIFY TRUVU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIA N 13 versus PYLARIFY TRUVU.
AMMONIA N 13 vs PYLARIFY TRUVU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonia N 13 is a radioactive diagnostic agent that is used as a tracer for positron emission tomography (PET) imaging. After intravenous injection, it distributes in the body and is taken up by cells, particularly in the myocardium and brain, via active transport and passive diffusion. Its accumulation reflects regional blood flow and metabolic activity.
PYLARIFY is a PSMA-targeted PET imaging agent composed of a urea-based PSMA ligand (piflufolastat) labeled with fluorine-18. It binds to prostate-specific membrane antigen (PSMA) on prostate cancer cells, allowing PET imaging for detection of PSMA-positive lesions.
1110-1850 MBq (30-50 mCi) intravenous bolus for PET imaging; single dose per imaging session. No repeated dosing within 24 hours.
1 mg/kg intravenously every 3 months.
None Documented
None Documented
9–12 minutes (blood) for ammonia; incorporation into glutamine may extend effective half-life for imaging purposes; rapid clearance limits toxicity.
Terminal elimination half-life: approximately 77 hours (range 68-85 hours) in patients with prostate cancer. This supports a 2-week dosing interval for single-photon emission computed tomography (SPECT) imaging.
Primary renal excretion; >95% eliminated as unchanged ammonia via glomerular filtration and tubular secretion. Minimal biliary/fecal excretion.
Renal excretion: approximately 93% (3% unchanged, 97% as metabolites). Fecal excretion: approximately 5%. Biliary excretion is negligible.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical